Complications by immunosuppressive therapy after liver transplantation - A retrospective 12-year analysis of the transplant center Bonn;Komplikationen durch immunsuppressive therapie nach lebertransplantation - Eine retrospektive 12-jahres-analyse des transplantationszentrums Bonn

Chirurgische Gastroenterologie Interdisziplinar

Volumn 24, Issue 3, 2008, Pages 226-233

  Stoffels, Burkhard ^a   Tolba, Rene H ^a,b,e   Schildberg, Frank A ^b   Wolff, Martin ^c   Lauschke, Holger ^d   Kalff, Jörg C ^a   Hirner, Andreas ^a  

^a Klinik und Poliklinik für Allgemein Viszeral Thorax und Gefäßchirurgie

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Klinikum Hanau

^d Klinik für Allgemein Viszeral und Unfallchirurgie   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Immunosuppression; Liver transplantation; Renal insufficiency

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; OPTORAL; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; HOSPITAL COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 53349175577     PISSN: 01779990     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151306     Document Type: Article

References (38)

1. Pfitzmann R, Neuhaus P: Fortschritte auf dem Gebiet der Lebertransplantation. Chir Gastroenterol 2004;20(suppl 1):28-35.
2. Starzl TE, Demetris AJ, Van Thiel D: Liver transplantation (2). N Engl J Med 1989;321:1092-1099.
3. Nadalin S, Malagó M, Broelsch CE: Steigerung der Organverfügbarkeit durch Leberlebendspende. Chir Gastroenterol 2002;18(suppl 1):30-33.
4. Bechstein WO, Zapletal C: Spenderorgane im Grenzbereich: Leber. Chir Gastroenterol 2002;18(suppl 1):24-28.
5. Canelo R, Braun F, Sattler B, Ringe B: Sollten Spenderlebern mit ausgeprägter Steatose zur Transplantation verwendet werden? Chir Gastroenterol 1998;14:323-328.
6. Shames BD, D'Alessandro AM, Krichevsky A, Sollinger HW: Organ donation after cardiac death. Chir Gastroenterologie 2002;18(suppl 1):39-41.
7. BANFF schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
8. MacDonald A: Improving tolerability of immunosuppressive regimens. Transplantation 2001;72:S105-S112.
9. Ketzler K, Losse H: [Dialysis and kidney transplantation - from the viewpoint and as a function of the board of trustees for home dialysis and kidney transplantation]. Internist (Berl) 1983;24:525-529.
10. Lynn M, Abreo K, Zibari G, McDonald J: End-stage renal disease in liver transplants. Clin Transplant 2001;15(suppl 6):66-69.
11. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
12. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB: End-stage renal disease (ESRD) after orthotopic liver transplantation (oLTx) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934-1939.
13. Braun N, Dette S, Viebahn R: Impairment of renal function following liver transplantation. Transplant Proc 2003;35:1458-1460.
14. Herrero JI, Quiroga J, Sangro B, Girala M, Gomez-Manero N, Pardo F, Alvarez-Cienfuegos J, Prieto J: Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999;5:414-420.
15. Gerona S, Laudano O, Macias S, San Roman E, Galdame O, Torres O, Sorkin E, Ciardullo M, de Santibanes E, Mastai R: [Renal failure in patients with liver transplant: incidence and predisposing factors]. Acta Gastroenterol Latinoam 1997;27:113-117.
16. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N: Continued influence of preoperative renal function on outcome of orthotopic liver transplant (oLTx) in the US: where will MELD lead us? Am J Transplant 2006;6:2651-2659.
17. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T: Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006;26:834-839.
18. Demirag A, Buhler LH, Majno P, Berney T, Chilcott M, Giostra E, Morel P, Mentha G: Medical problems occurring during the long-term follow-up after liver transplantation. Swiss Surg 2003;9:237-241.
19. Steinmuller TH, Stockmann M, Bechstein WO, Settmacher U, Jonas S, Neuhaus P: Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:401-405.
20. Reisaeter AV, Hartmann A: Risk factors and incidence of posttransplant diabetes mellitus. Transplant Proc 2001;33:8S-18S.
21. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002;25:583-592.
22. John PR, Thuluvath PJ: Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8:708-713.
23. Pichlmayr R, Winkler M, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Groth CG, Bismuth H: Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. Transplant Proc 1997;29:2499-2502.
24. Margarit C, Rimola A, Gonzalez-Pinto I, Cuervas-Mons V, Edo A, Andreu H, Moreno-Gonzalez E, Calleja JL: Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int 1998;11(suppl 1):S260-S266.
25. Ghaus N, Bohlega S, Rezeig M: Neurological complications in liver transplantation. J Neurol 2001;248:1042-1048.
26. Moreno JM, Rubio E, Gomez A, Lopez-Monclus J, Herreros A, Revilla J, Navarrete E, Sanchez TV, Jimenez M, Cuervas-Mons V: Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003;35:1874-1876.
27. Pfitzmann R, Klupp J, Langrehr JM, Uhl M, Neuhaus R, Settmacher U, Steinmuller T, Neuhaus P: Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003;76:130-136.
28. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J: Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003;76:98-102.
29. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH: Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003;16:504-509.
30. Raimondo ML, Dagher L, Papatheodoridis GV, Rolando N, Patch DW, Davidson BR, Rolles K, Burroughs AK: Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003;75:186-190.
31. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R: Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19:199-206.
32. Jorga A, Johnston A: Novel therapies in transplantation. Expert Opin Investig Drugs 2005;14:295-303.
33. Kaplan B: Enteric-coated mycophenolate sodium (myfortic(®)): An overview of current and future use in transplantation. Drugs 2006;66:1-8.
34. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R: Experience with the use of sirolimus in liver transplantation - use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000;6:734-740.
35. Jorga A, Johnston A: Novel therapies in transplantation. Expert Opin Investig Drugs 2005;14:295-303.
36. Nashan B: Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002;11:1845-1857.
37. Emre S, Gondolesi G, Polat K, Ben Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM: Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001;7:220-225.
38. Niemeyer G, Koch M, Light S, Kuse ER, Nashan B: Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002;2:454-460.